Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil

The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distr...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 68; no. 1; pp. 8 - 9
Main Authors:	SCHEITHAUER, W, SCHENK, T, CZEJKA, M
Format:	Journal Article
Language:	English
Published:	Basingstoke Nature Publishing Group 01-07-1993
Subjects:	Antineoplastic agents Biological and medical sciences Chemotherapy Colonic Neoplasms - drug therapy Drug Resistance Epirubicin - pharmacokinetics Epirubicin - therapeutic use Female Half-Life Humans Male Medical sciences Metabolic Clearance Rate Middle Aged Pharmacology. Drug treatments Rectal Neoplasms - drug therapy Verapamil - therapeutic use Human Antineoplastic agent Malignant tumor Antibiotic Chemotherapy Treatment Multiple resistance Rectum Digestive diseases Intestinal disease Reversibility Advanced stage Drug interaction Anthracyclins Colon Pharmacokinetics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The potential for a pharmacokinetic interaction between epirubicin and the second-generation multidrug resistance modulating agent D-verapamil (DVPM) has been investigated in six patients with advanced colorectal cancer. Our results indicate that a significant interaction takes place. Enhanced distribution of epirubicin from the serum and altered disposition might, in fact, explain the increased level of myelotoxicity in this pilot as well as in other clinical phase II studies involving DVPM.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0007-0920 1532-1827
DOI:	10.1038/bjc.1993.277